HSP90 and the chaperoning of cancer
The DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Standing watch over the proteome, molecular chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival. This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution. Pharmacologically 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HSP90AB1 is commonly overexpressed in a variety of cancers, with this upregulation typically linked to poor prognostic outcomes and increased resistance to standard chemotherapy and radiotherapy treatments [12, 42, 43].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [43]
In the citing paper
“This role as a potentiator for genetic variation has been observed in fungi as well as mammalian cancer cells20,88,135,136.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
In the citing paper
“Second, Hsp90 can enable the phenotypic effects of new mutations either by stabilizing mutant regulators or by stabilizing non-mutant regulators that mediate signalling required for adaptation.”
From Fungal Hsp90: a biological transistor that tunes cellular outputs to thermal inputs (2012) · cites this paper as [88]
Citations
Cites
Hsp90 as a capacitor for morphological evolution
Rutherford, S. L., & Lindquist, S. (1998) · Nature · doi:10.1038/24550 · Cited by 2,270 · cited 1×
“melanogaster and Arabidopsis thaliana model systems that HSP90 can conceal inherent genetic variation within populations of organism”
BackgroundSelf-citationWhitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Self-citationA high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Kamal, A., Thao, L., Sensintaffar, J., Zhang, L., Boehm, M. F., Fritz, L. C., & Burrows, F. J. (2003) · Nature · doi:10.1038/nature01913 · Cited by 1,387 · cited 1×
“By contrast, in normal cells, there is a substantial pool of free HSP90 dimers that have low ATPase activity and low drug affinit”
BackgroundHsp90 as a capacitor of phenotypic variation
Queitsch, C., Sangster, T. A., & Lindquist, S. (2002) · Nature · doi:10.1038/nature749 · Cited by 1,372
Self-citationStebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,364
Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1997) · Cell · doi:10.1016/s0092-8674(00)80314-1 · Cited by 1,265
Structure of TPR Domain–Peptide Complexes
Scheufler, C., Brinker, A., Bourenkov, G., Pegoraro, S., Moroder, L., Bartunik, H., Hartl, F. U., & Moarefi, I. (2000) · Cell · doi:10.1016/s0092-8674(00)80830-2 · Cited by 1,188
Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death
Jolly, C. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1564 · Cited by 1,048 · cited 1×
“Several detailed reviews are available that address the molecular and cellular biology of the heat-shock respons”
BackgroundThe 90-kDa Molecular Chaperone Family
Csermely, P., Schnaider, T., So″ti, C., Prohászka, Z., & Nardai, G. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00013-8 · Cited by 1,028
Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., & Pearl, L. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980403y · Cited by 1,004 · cited 1×
“Drug binding at the N-terminus of HSP90 has now been shown to alter many of its normal function”
Background
Research works printed but not linked: 2
- McCollum, A., Toft, D. O. & Erlichman, C. Geldanamycin enhances cisplatin cytotoxicity through loss of Akt activation in A549 cells. Clin. Cancer Res. 9 (Suppl.), 6178 (2003).
- Barbosa, J. A. et al. Discovery of novel small molecule Hsp90 complex inhibitors using a forward chemical genetics approach. Clin. Cancer Res. 9 (Suppl.), 6176 (2003).
Cited by
Items 201–300 of 1,008
Zhang, X.-H., Qin-Ma, Wu, H.-P., Khamis, M. Y., Li, Y.-H., Ma, L.-Y., & Liu, H.-M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01782 · Cited by 143
Drugging the addict: non‐oncogene addiction as a target for cancer therapy
Nagel, R., Semenova, E. A., & Berns, A. J. M. (2016) · EMBO Reports · doi:10.15252/embr.201643030 · Cited by 175
“HSF1 is induced by various protein-denaturing stresses and, among others, regulates the expression of the chaper-ones HSP70 and HSP90 [27,28].”
Tumor Selectivity of Hsp90 Inhibitors: The Explanation Remains Elusive
Chiosis, G., & Neckers, L. (2006) · ACS Chemical Biology · doi:10.1021/cb600224w · Cited by 156
Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells
Siegelin, M. D., Dohi, T., Raskett, C. M., Orlowski, G. M., Powers, C. M., Gilbert, C. A., Ross, A. H., Plescia, J., & Altieri, D. C. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44855 · Cited by 157
Current developments of targeting the p53 signaling pathway for cancer treatment
Huang, J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107720 · Cited by 157
Lancet, J. E., Gojo, I., Burton, M., Quinn, M. F., Tighe, S., Kersey, K., Zhong, Z., Albitar, M. X., Bhalla, K. N., Hannah, A. L., et al. (2010) · Leukemia · doi:10.1038/leu.2009.292 · Cited by 156
Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer
Rodina, A., Vilenchik, M., Moulick, K., Aguirre, J., Kim, J., Chiang, A., Litz, J., Clement, C. C., Kang, Y., She, Y., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.10 · Cited by 169
Emerging Functions of Human IFIT Proteins in Cancer
Pidugu, V. K., Pidugu, H. B., Wu, M., Liu, C., & Lee, T.-C. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00148 · Cited by 171
“Hsp90 is a ubiquitously expressed molecular chaperone in the cells that regulates a multitude of cellular processes, such as client kinase folding, maturation, and degradation (Whitesell and Lindquist, 2005).”
BackgroundInfluentialMeta-analysis of heat- and chemically upregulated chaperone genes in plant and human cells
Finka, A., Mattoo, R. U. H., & Goloubinoff, P. (2010) · Cell Stress and Chaperones · doi:10.1007/s12192-010-0216-8 · Cited by 172
“Bridged by TPR-containing cochaperones, both chaperones can form functional supercomplexes that modify in a yet ill-defined ATP-dependent mechanism, the structure, and consequently the function, of hundreds of the so-called native “client” proteins in the cell (Whitesell and Lindquist 2005; Zhao et al. 2005).”
BackgroundMorano, K. A. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1391.018 · Cited by 154
Sidera, K., Gaitanou, M., Stellas, D., Matsas, R., & Patsavoudi, E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m701803200 · Cited by 167
Kourtis, N., Moubarak, R. S., Aranda-Orgillés, B., Lui, K. P., Aydin, I. T., Trimarchi, T., Darvishian, F., Salvaggio, C., Zhong, J., Bhatt, K., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3121 · Cited by 165
“Upon stress, HSF1 induces gene expression of heat-shock proteins (HSPs), which act as molecular chaperones and restore protein homeostasis 1-3 .”
Gedunin Inactivates the Co-chaperone p23 Protein Causing Cancer Cell Death by Apoptosis
Patwardhan, C. A., Fauq, A. H., Peterson, L. B., Miller, C. A., Blagg, B. S. J., & Chadli, A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.427328 · Cited by 156
“myeloma, breast, and prostate cancers (3, 15).”
Turbyville, T. J., Wijeratne, E. M. K., Liu, M. X., Burns, A. M., Seliga, C. J., Luevano, L. A., David, C. L., Faeth, S. H., Whitesell, L., & Gunatilaka, A. A. L. (2006) · Journal of Natural Products · doi:10.1021/np058095b · Cited by 150
Self-citationUsing the Heat-Shock Response To Discover Anticancer Compounds that Target Protein Homeostasis
Santagata, S., Xu, Y.-M., Wijeratne, E. M. K., Kontnik, R., Rooney, C., Perley, C. C., Kwon, H., Clardy, J., Kesari, S., Whitesell, L., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb200353m · Cited by 147
“Anthothecol (1), cedrelone (2), gedunin (3), 7-desacetoxy-6,7-dehydrogedunin (4) were from Gaia Chemical.”
Self-citationPeng, C., Brain, J. M., Hu, Y., Goodrich, A., Kong, L., Grayzel, D., Pak, R. H., Read, M. A., & Li, S. (2007) · Blood · doi:10.1182/blood-2006-10-054098 · Cited by 155
Morra, G., Verkhivker, G., & Colombo, G. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000323 · Cited by 148
“cellular compartments [7] of a wide range of client proteins [4,7,8].”
BackgroundBrodsky, J. L. (2007) · Biochemical Journal · doi:10.1042/bj20061890 · Cited by 151
Richardson, P. G. G., Mitsiades, C. S., Laubach, J. P., Lonial, S., Chanan-Khan, A. A., & Anderson, K. C. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08360.x · Cited by 157
Ohkubo, S., Kodama, Y., Muraoka, H., Hitotsumachi, H., Yoshimura, C., Kitade, M., Hashimoto, A., Ito, K., Gomori, A., Takahashi, K., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0219 · Cited by 145
“The molecular chaperone heat shock protein 90 (HSP90) is a highly conserved protein that regulates the activity and stability of a diverse range of "client" proteins (1, 2).”
BackgroundHance, M. W., Dole, K., Gopal, U., Bohonowych, J. E. S., Jezierska‐Drutel, A., Neumann, C. A., Liu, H., Garraway, I. P., & Isaacs, J. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.389015 · Cited by 152
Anticancer Inhibitors of Hsp90 Function
(2016) · Advances in Cancer Research · doi:10.1016/bs.acr.2015.12.001 · Cited by 146
“4) by inhibitors when given at or near their maximally tolerated dose may represent a fundamental impediment to their clinical efficacy (Whitesell & Lindquist, 2005).”
InfluentialA Rhizosphere Fungus Enhances Arabidopsis Thermotolerance through Production of an HSP90 Inhibitor
McLellan, C. A., Turbyville, T. J., Wijeratne, E. M. K., Kerschen, A., Vierling, E., Queitsch, C., Whitesell, L., & Gunatilaka, A. A. L. (2007) · Plant Physiology · doi:10.1104/pp.107.101808 · Cited by 146
“…understanding the mechanisms and activities of small molecule HSP90 inhibitors in mammalian systems, especially for possible treatment of cancers (Whitesell and Lindquist, 2005), there has been virtually no investigation of the impact of production of HSP90 inhibitors on plant-microorganism…”
BackgroundSelf-citationEndogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy
Spiegel, S., Milstien, S., & Grant, S. (2012) · Oncogene · doi:10.1038/onc.2011.267 · Cited by 141
“Hsp90 is an abundant cellular chaperone whose overexpression in tumor cells correlates with resistance to chemotherapy (Whitesell and Lindquist, 2005).”
Hypoxia‐Responsive Gene Editing to Reduce Tumor Thermal Tolerance for Mild‐Photothermal Therapy
Li, X., Pan, Y., Chen, C., Gao, Y., Liu, X., Yang, K., Luan, X., Zhou, D., Zeng, F., Han, X., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202107036 · Cited by 148
Chatterjee, M., Jain, S., Stühmer, T., Andrulis, M., Ungethüm, U., Kuban, R.-J., Lorentz, H., Bommert, K., Topp, M., Krämer, D., et al. (2007) · Blood · doi:10.1182/blood-2006-05-024372 · Cited by 144
“Hsp90s are overexpressed in many cancers and it is presumed that they are required to sustain aberrant signaling in malignant cells.(14) Several components of tumor cell-associated growth and survival pathways have been found to be Hsp90 clients, and Hsp90s are thus thought to sustain functional expression of oncoprot…”
BackgroundAdapting to stress — chaperome networks in cancer
Joshi, S., Wang, T., Araujo, T. L. S., Sharma, S., Brodsky, J. L., & Chiosis, G. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0020-9 · Cited by 148
Physiological Functions of Heat Shock Proteins
Shan, Q., Ma, F., Wei, J., Li, H., Ma, H., & Sun, P. (2020) · Current Protein & Peptide Science · doi:10.2174/1389203720666191111113726 · Cited by 138
Zhang, J., Yao, M., Xia, S., Zeng, F., & Liu, Q. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00682-7 · Cited by 126
Heat Shock Proteins in Diabetes and Wound Healing
Atalay, M., Oksala, N., Lappalainen, J., Laaksonen, D. E., Sen, C. K., & Roy, S. (2009) · Current Protein and Peptide Science · doi:10.2174/138920309787315202 · Cited by 165
Sharp, S. Y., Prodromou, C., Boxall, K. J., Powers, M. V., Holmes, J. L., Box, G., Matthews, T. P., Cheung, K.-M. J., Kalusa, A., James, K. E., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0149 · Cited by 156
“such as steroid hormone receptors and protein kinases (1, 2).”
BackgroundFiskus, W., Ren, Y., Mohapatra, A., Bali, P., Mandawat, A., Rao, R., Herger, B., Yang, Y., Atadja, P., Wu, J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3093 · Cited by 140
Hsp90 inhibitors reduce influenza virus replication in cell culture
Chase, G. P., Deng, T., Fodor, E., Leung, B. W., Mayer, D., Schwemmle, M., & Brownlee, G. G. (2008) · Virology · doi:10.1016/j.virol.2008.04.040 · Cited by 154
“17-allylamino-demethoxygeldanamycin (17-AAG), a geldanamycin (GA) analogue] (Whitesell and Lindquist, 2005).”
BackgroundInfluentialDuval, M., Le Bœuf, F., Huot, J., & Gratton, J.-P. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-05-0467 · Cited by 139
“Heat-shock protein 90 kDa (Hsp90) is a multifunctional molecular chaperone, and its role in the prevention of protein aggregation and in the refolding of denatured proteins has been studied in much detail (Whitesell and Lindquist, 2005).”
BackgroundLeu, J. I.-J., Pimkina, J. S., Pandey, P., Murphy, M. E., & George, D. L. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0019 · Cited by 154
“As a control for these studies, we compared the effects of PES with that of the well-established HSP90 inhibitor, 17-AAG, which interacts with the N-terminal region of HSP90 and inhibits its ATPase activity; this leads to client protein degradation via the ubiquitin-proteasome pathway (14, 15).”
MethodCostantino, E., Maddalena, F., Calise, S. J., Piscazzi, A., Tirino, V., Fersini, A., Ambrosi, A., Neri, V., Esposito, F., & Landriscina, M. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.018 · Cited by 152
“Hsp90 chaperones are, indeed, required for the activity of several key regulators of apoptosis and through these associations may confer survival advantages to tumor cells [22].”
BackgroundConformational Switching of the Molecular Chaperone Hsp90 via Regulated Phosphorylation
Soroka, J., Wandinger, S. K., Mäusbacher, N., Schreiber, T., Richter, K., Daub, H., & Buchner, J. (2012) · Molecular Cell · doi:10.1016/j.molcel.2011.12.031 · Cited by 139
“Thus Hsp90 can be seen as a hub for the conformational regulation of proteins in the eukaryotic cell (Whitesell and Lindquist, 2005).”
Maloney, A., Clarke, P. A., Naaby-Hansen, S., Stein, R., Koopman, J.-O., Akpan, A., Yang, A., Zvelebil, M., Cramer, R., Stimson, L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2968 · Cited by 138
“The natural product HSP90 inhibitors radicicol, geldanamycin, and their derivatives exert their antitumor effect by inhibiting the intrinsic ATPase activity of HSP90, resulting in degradation of HSP90 client proteins via the ubiquitin-proteasome pathway (4, 5).”
BackgroundALK inhibitors in non-small cell lung cancer: the latest evidence and developments
Sullivan, I., & Planchard, D. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015617355 · Cited by 155
“Inhibition of HSP90 activity results in aggregation or proteasomal degradation of these proteins, which in turn promotes the simultaneous disruption of numerous oncogenic signalling pathways critical for tumour cell proliferation and survival [Whitesell and Lindquist, 2005].”
BackgroundPark, H.-K., Yoon, N. G., Lee, J.-E., Hu, S., Yoon, S., Kim, S. Y., Hong, J.-H., Nam, D., Chae, Y. C., Park, J. B., et al. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0360-x · Cited by 129
Gopal, U., Bohonowych, J. E., Lema-Tome, C., Liu, A., Garrett-Mayer, E., Wang, B., & Isaacs, J. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017649 · Cited by 136
“Hsp90 has a well-established intracellular role in mediating the folding and activity of numerous signaling proteins, many of which contribute to malignancy [13,14,15].”
BackgroundBurlison, J. A., Avila, C., Vielhauer, G. A., Lubbers, D. J., Holzbeierlein, J. M., & Blagg, B. S. J. (2008) · The Journal of Organic Chemistry · doi:10.1021/jo702191a · Cited by 138
Aalinkeel, R., Bindukumar, B., Reynolds, J. L., Sykes, D. E., Mahajan, S. D., Chadha, K. C., & Schwartz, S. A. (2008) · The Prostate · doi:10.1002/pros.20845 · Cited by 137
“High levels of Hsp90 expression also correlate with increased drug resistance in human glioma [56] and multiple myeloma [57] cells and in other human cancers [58].”
Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells
Chen, S., & Sang, N. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25283 · Cited by 145
Rice, J. W., Veal, J. M., Fadden, R. P., Barabasz, A. F., Partridge, J. M., Barta, T. E., Dubois, L. G., Huang, K. H., Mabbett, S. R., Silinski, M. A. R., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.24047 · Cited by 137
Heat Shock Protein 90 Is Required for Conidiation and Cell Wall Integrity in Aspergillus fumigatus
Lamoth, F., Juvvadi, P. R., Fortwendel, J. R., & Steinbach, W. J. (2012) · Eukaryotic Cell · doi:10.1128/ec.00032-12 · Cited by 136
“The heat shock protein 90 (Hsp90) is a molecular chaperone present in all eukaryotes (39).”
Kim, S. H., Iyer, K. R., Pardeshi, L., Muñoz, J. F., Robbins, N., Cuomo, C. A., Wong, K. H., & Cowen, L. E. (2019) · mBio · doi:10.1128/mbio.02529-18 · Cited by 136
“We postulate that this was in part a consequence of the fact that depletion of Hsp90 results in cellular consequences different from those resulting from locking the available Hsp90 pool in a particular state in its chaperone cycle (35).”
BackgroundUbr1 and Ubr2 Function in a Quality Control Pathway for Degradation of Unfolded Cytosolic Proteins
Nillegoda, N. B., Theodoraki, M. A., Mandal, A. K., Mayo, K. J., Ren, H. Y., Sultana, R., Wu, K., Johnson, J., Cyr, D. M., & Caplan, A. J. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-02-0098 · Cited by 135
“GA is a competitive inhibitor of Hsp90’s ATPase, and its action results in the rapid degradation of protein kinases and other clients by the ubiquitin/proteasome system (Whitesell and Lindquist, 2005; Caplan et al., 2007b).”
BackgroundStecklein, S. R., Kumaraswamy, E., Behbod, F., Wang, W., Chaguturu, V., Harlan-Williams, L. M., & Jensen, R. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203326109 · Cited by 135
“HSP90 chaperones “client” proteins into their native conformations, regulating multiple aspects of protein function (20).”
BackgroundTargeting the oncogene and kinome chaperone CDC37
Gray, P. J., Prince, T. L., Cheng, J., Stevenson, M. A., & Calderwood, S. K. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2420 · Cited by 147
“The role of molecular chaperones in cancer was first characterized with regard to heat-shock protein 90 (HSP90; for review see Ref”
BackgroundConnor, J. H., McKenzie, M. O., Parks, G. D., & Lyles, D. S. (2007) · Virology · doi:10.1016/j.virol.2006.12.026 · Cited by 146
“Thus, this compound has already passed many of the hurdles that confront successful drug development, and it or other Hsp90 inhibitors in development (Whitesell and Lindquist, 2005) are likely to be clinically viable.”
BackgroundLi, R., Pourpak, A., & Morris, S. W. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9002395 · Cited by 144
Holmes, J. L., Sharp, S. Y., Hobbs, S., & Workman, P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3268 · Cited by 147
Targeting the Cytoprotective Chaperone, Clusterin, for Treatment of Advanced Cancer
Zoubeidi, A., Chi, K., & Gleave, M. E. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2917 · Cited by 142
“Chaperones act as genetic buffers stabilizing the phenotype of various cells and organisms at times of environmental stress, enhancing the Darwinian fitness of cells during transformation, progression, and treatment resistance (11).”
BackgroundShibata, T., Saito, S., Kokubu, A., Suzuki, T., Yamamoto, M., & Hirohashi, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0384 · Cited by 128
Salmans, M., Zhao, F. R., & Andersen, B. (2013) · Breast Cancer Research · doi:10.1186/bcr3408 · Cited by 141
Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor
Khandelwal, A., Kent, C. N., Balch, M., Peng, S., Mishra, S. J., Deng, J., Day, V. W., Liu, W., Subramanian, C., Cohen, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02013-1 · Cited by 122
“Introduction of the smaller 4-formyl group (4) led to both improved selectivity and affinity for Hsp90β (Kd = 310 nM versus 1.”
HSP90-buffered genetic variation is common in Arabidopsis thaliana
Sangster, T. A., Salathia, N., Lee, H. N., Watanabe, E., Schellenberg, K., Morneau, K., Wang, H., Undurraga, S., Queitsch, C., & Lindquist, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712210105 · Cited by 131
Self-citationLoss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis
Dai, C., Santagata, S., Tang, Z., Shi, J., Cao, J., Kwon, H., Bronson, R. T., Whitesell, L. J., & Lindquist, S. L. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62727 · Cited by 140
“Dysregulation of the protein translation machinery (52), imbalanced protein production due to aneuploidy (53,54) and accumulation of mutated, highly chaperone-dependent oncoproteins all strain the chaperone machinery (55-57).”
Self-citationLeav, I., Plescia, J., Goel, H. L., Li, J., Jiang, Z., Cohen, R. J., Languino, L. R., & Altieri, D. C. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090521 · Cited by 133
Fu, Y., Xu, X., Huang, D., Cui, D., Liu, L., Liu, J., He, Z., Liu, J., Zheng, S., & Luo, Y. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.09.007 · Cited by 139
“In addition, the tremendous progress has been made in developing Hsp90 inhibitors as anticancer agents (Whitesell and Lindquist, 2005).”
BackgroundInfluentialEpigenetic polypharmacology: A new frontier for epi‐drug discovery
Tomaselli, D., Lucidi, A., Rotili, D., & Mai, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21600 · Cited by 119
“Most importantly, the hyperacetylation mediated by panobinostat 6 at HSP90 level restores the physiological degradation of different oncoproteins, including epidermal growth factor receptor (EGFR) and its downstream transducers.(141) In addition, it has been shown that HDACi reverses the repression of microRNAs (miRNA…”
BackgroundHsp90 orchestrates stress response signaling governing fungal drug resistance
Cowen, L. E. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000471 · Cited by 130
“Notably, Hsp90 inhibitors are in advanced phase clinical development as anticancer agents [5].”
The Evolution of Therapies in Non-Small Cell Lung Cancer
Boolell, V., Alamgeer, M., Watkins, D. N., & Ganju, V. (2015) · Cancers · doi:10.3390/cancers7030864 · Cited by 141
“Heat Shock Protein 90 (Hsp 90) is a protein involved in regulating the correct folding, stability and function of numerous proteins involved in normal cellular function as well as tumourigenesis [88].”
BackgroundPharmacological Targeting of the Hsp70 Chaperone
Patury, S., Miyata, Y., & Gestwicki, J. E. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789895674 · Cited by 151
“Briefly, Hsp90 is thought to both enhance the cellular capacity to accommodate otherwise toxic proteins, while also preventing the onset of apoptosis by stabilizing pro-survival substrates, such as Akt [84-89].”
HSP90 Shapes the Consequences of Human Genetic Variation
Karras, G. I., Yi, S., Sahni, N., Fischer, M., Xie, J., Vidal, M., D’Andrea, A. D., Whitesell, L., & Lindquist, S. (2017) · Cell · doi:10.1016/j.cell.2017.01.023 · Cited by 130
“For example, HSP90 promotes the oncogenic hyperactivity and malignant potential of many kinases by assisting these intrinsically unstable proteins to fold and function (Whitesell and Lindquist, 2005).”
Self-citationSgt1p Is a Unique Co-chaperone That Acts as a Client Adaptor to Link Hsp90 to Skp1p
Catlett, M. G., & Kaplan, K. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603847200 · Cited by 127
A postgenomic view of the heat shock proteins in kinetoplastids
Folgueira, C., & Requena, J. M. (2007) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2007.00069.x · Cited by 129
Du, S. J., Li, H., Bian, Y., & Zhong, Y. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707330105 · Cited by 126
Protein Interactions, Post-translational Modifications and Topologies in Human Cells
Chavez, J. D., Weisbrod, C. R., Zheng, C., Eng, J. K., & Bruce, J. E. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.024497 · Cited by 126
“HSP90 is one such homodimer that has significant clinical significance in cancer (38).”
BackgroundStructural and Functional Profiling of the Human Histone Methyltransferase SMYD3
Foreman, K. W., Brown, M., Park, F., Emtage, S., Harriss, J., Das, C., Zhu, L., Crew, A., Arnold, L., Shaaban, S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022290 · Cited by 120
Targeting heat shock proteins in metastatic castration-resistant prostate cancer
Azad, A., Zoubeidi, A., Gleave, M. E., & Chi, K. N. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.320 · Cited by 136
de la Roche, M., Rutherford, T. J., Gupta, D., Veprintsev, D. B., Saxty, B., Freund, S. M., & Bienz, M. (2012) · Nature Communications · doi:10.1038/ncomms1680 · Cited by 120
“This may render oncogenic β-catenin particularly vulnerable and prone to degradation, a property shared by other oncogenes whose stability is reliant on chaperones such as HSP90 (ref”
BackgroundRedox regulation of the stability of the SUMO protease SENP3 via interactions with CHIP and Hsp90
Yan, S., Sun, X., Xiang, B., Cang, H., Kang, X., Chen, Y., Li, H., Shi, G., Yeh, E. T. H., Wang, B., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.245 · Cited by 131
“Some Hsps, mainly members of the Hsp70 family and its co-chaperones, select and direct aberrant proteins to the proteasome or lysosome for degradation (Whitesell and Lindquist, 2005).”
BackgroundStructural analysis of the interaction between Hsp90 and the tumor suppressor protein p53
Hagn, F., Lagleder, S., Retzlaff, M., Rohrberg, J., Demmer, O., Richter, K., Buchner, J., & Kessler, H. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2114 · Cited by 127
Heat Shock Protein 90 Inhibitors. A Text Book Example of Medicinal Chemistry?
Janin, Y. L. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050759r · Cited by 134
Real-Time Imaging of HIF-1α Stabilization and Degradation
Moroz, E., Carlin, S., Dyomina, K., Burke, S., Thaler, H. T., Blasberg, R., & Serganova, I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005077 · Cited by 118
“The degradation of HIF-1a is also regulated in an O2independent manner by the competitive binding to either heat shock protein 90 (HSP90), which stabilizes the protein [16,17], or to the anchoring protein (RACK1), which leads to HIF-1a degradation by an oxygen-independent process [18].”
BackgroundStructural basis for species-selective targeting of Hsp90 in a pathogenic fungus
Whitesell, L., Robbins, N., Huang, D. S., McLellan, C. A., Shekhar-Guturja, T., LeBlanc, E. V., Nation, C. S., Hui, R., Hutchinson, A., Collins, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08248-w · Cited by 124
Self-citationGaspar, N., Sharp, S. Y., Pacey, S., Jones, C., Walton, M. I., Vassal, G., Eccles, S. A., Pearson, A. D. J., & Workman, P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3131 · Cited by 124
“Through its role in regulating the conformation, stability and function of several key oncogenic client proteins, HSP90 seems to be essential in maintaining malignant transformation and in increasing the survival, growth, and invasive potential of cancer cells (1, 2).”
BackgroundHsp90 and Its Co-Chaperones in Neurodegenerative Diseases
Bohush, A., Bieganowski, P., & Filipek, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20204976 · Cited by 133
Song, X., Wang, X., Zhuo, W., Shi, H., Feng, D., Sun, Y. X., Liang, Y., Fu, Y., Zhou, D., & Luo, Y. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.181941 · Cited by 128
Unfolding the Role of Large Heat Shock Proteins: New Insights and Therapeutic Implications
Zuo, D., Subjeck, J. R., & Wang, X. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00075 · Cited by 124
“Although therapeutic inhibition of Hsp90 has been evaluated in the context of cancer treatment (200), growing evidence indicates that Hsp90 inhibitors also provide benefits for treatment of inflammatory disorders.”
BackgroundNoguchi, M., Yu, D., Hirayama, R., Ninomiya, Y., Sekine, E., Kubota, N., Ando, K., & Okayasu, R. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.094 · Cited by 122
“Heat shock protein 90 (Hsp90) is a molecular chaperone that plays a critical role in an extensive network of cellular signaling pathways [14,15].”
BackgroundHSP DNAJB8 Controls Tumor-Initiating Ability in Renal Cancer Stem–like Cells
Nishizawa, S., Hirohashi, Y., Torigoe, T., Takahashi, A., Tamura, Y., Mori, T., Kanaseki, T., Kamiguchi, K., Asanuma, H., Morita, R., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3062 · Cited by 127
“HSPs, especially HSP90, are overexpressed in a wide range of human cancers, allowing mutant proteins to be retained in cancer cells and to confer resistance to cytotoxic therapies (39).”
BackgroundTargeted induction of apoptosis for cancer therapy: current progress and prospects
Bremer, E., van Dam, G., Kroesen, B. J., de Leij, L., & Helfrich, W. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.06.002 · Cited by 140
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models
Whitesell, L. J., Santagata, S., Mendillo, M. L., Lin, N., Proia, D. A., & Lindquist, S. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421323111 · Cited by 121
Self-citationRecent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment
Peng, X., Sun, Z., Kuang, P., & Chen, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112831 · Cited by 121
Heat shock protein 90: biological functions, diseases, and therapeutic targets
Wei, H., Zhang, Y., Jia, Y., Chen, X., Niu, T., Chatterjee, A., He, P., & Hou, G. (2024) · MedComm · doi:10.1002/mco2.470 · Cited by 131
“115 Cancer represents a significant global health challenge.”
BackgroundPlasticity of the Hsp90 chaperone machine in divergent eukaryotic organisms
Johnson, J. L., & Brown, C. (2009) · Cell Stress and Chaperones · doi:10.1007/s12192-008-0058-9 · Cited by 119
“Two recent reviews describe the role of Cdc37 in a variety of signaling cascades as well as what is known about the interactions of Cdc37 and Hsp90 with oncogenic kinases (Caplan et al. 2007; Whitesell and Lindquist 2005).”
Liu, C., Lou, W., Yang, J. C., Liu, L., Armstrong, C. M., Lombard, A. P., Zhao, R., Noel, O. D. V., Tepper, C. G., Chen, H.-W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07178-x · Cited by 117
HSP90 regulates cell survival via inositol hexakisphosphate kinase-2
Chakraborty, A., Koldobskiy, M. A., Sixt, K. M., Juluri, K. R., Mustafa, A. K., Snowman, A. M., van Rossum, D. B., Patterson, R. L., & Snyder, S. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711168105 · Cited by 118
“HSP90 is a promising target for the development of cancer chemotherapeutics because its inhibition simultaneously affects multiple oncogenic proteins (29, 30).”
BackgroundThe role of autophagy in targeted therapy for acute myeloid leukemia
Du, W., Xu, A., Huang, Y., Cao, J., Zhu, H., Yang, B., Shao, X., He, Q., & Ying, M. (2020) · Autophagy · doi:10.1080/15548627.2020.1822628 · Cited by 129
Morra, G., Potestio, R., Micheletti, C., & Colombo, G. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002433 · Cited by 122
“These homodimeric multidomain molecular chaperones are highly conserved from bacteria to eukaryotes and oversee the correct folding and conformational maturation of several client proteins [9,10,11,12,13].”
BackgroundHuman DNAJ in cancer and stem cells
Sterrenberg, J. N., Blatch, G. L., & Edkins, A. L. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.019 · Cited by 126
“As most chaperones do not function alone but rather as part of multi-protein complexes consisting of other chaperones, in addition to chaperone-regulating proteins known as co-chaperones [16,17].”
BackgroundHendriks, G., Derr, R. S., Misovic, B., Morolli, B., Calléja, F. M. G. R., & Vrieling, H. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfv323 · Cited by 113
Wang, H., Deng, G., Ai, M., Xu, Z., Mou, T., Yu, J., Liu, H., Wang, S., & Li, G. (2019) · Oncogene · doi:10.1038/s41388-018-0532-5 · Cited by 117
Heat shock proteins in hepatocellular carcinoma: Molecular mechanism and therapeutic potential
Wang, C., Zhang, Y., Guo, K., Wang, N., Jin, H., Liu, Y., & Qin, W. (2015) · International Journal of Cancer · doi:10.1002/ijc.29723 · Cited by 120
“The client proteins of HSP90 are involved in all stages of carcinogenesis, including proliferation, apoptosis, angiogenesis, invasion and metastasis.(33) Clusterin is an ATP-independent molecular chaperone with HSPs-like properties.”
Backgroundp53-A natural cancer killer: Structural insights and therapeutic concepts
Römer, L., Klein, C., Dehner, A., Kessler, H., & Buchner, J. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600611 · Cited by 93
Hsp70 Protein Complexes as Drug Targets
Assimon, V. A., Gillies, A. T., Rauch, J. N., & Gestwicki, J. E. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804143699 · Cited by 128
“What is the best way to chemically target Hsp70? One possible approach is to inhibit ATPase activity with competitive nucleotide analogs[20], as has been done with Hsp90 inhibitors [37].”
BackgroundDimerization of Hsp90 Is Required for in Vivo Function
Wayne, N., & Bolon, D. N. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703844200 · Cited by 114
Metadata
- Authors
- Whitesell, L., & Lindquist, S. L.
- Affiliations
- University of Arizona (US)
- Whitehead Institute for Biomedical Research (US)
- Corresponding author
- Whitesell, Luke
- ORCID
- Whitesell, Luke
- Venue
- Nature Reviews Cancer
- Published
- 2005-09-20
- Volume
- 5
- Issue
- 10
- Pages
- 761-772
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2022531767
- Cited by
- 2,502
- References
- 149
- Citations by year
- 2026: 81 · 2025: 87 · 2024: 83 · 2023: 97 · 2022: 90 · 2021: 113 · 2020: 123 · 2019: 142 · 2018: 99 · 2017: 116 · 2016: 126 · 2015: 152 · 2014: 154 · 2013: 153 · 2012: 167
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- HSP90, molecular chaperones, carcinogenesis, malignant transformation, somatic evolution, protein folding, proteome, anticancer drug targets, chaperone inhibition
- MeSH terms
- Animals, Humans, Neoplasms, Molecular Chaperones, HSP90 Heat-Shock Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.